Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

IBD management selector

Choose a PROFESSION LENS — conventional medical, dietary, naturopathic, or Indigenous/traditional — and enter the disease type, location and severity. Each lens gives evidence-graded options with its dated sources. The complementary lenses are ADJUNCTS, not replacements: moderate-to-severe IBD requires conventional medical/biologic therapy.

Guideline lens

Disease typechoose one

The decisive branch — 5-ASA is first-line for UC but recommended against in Crohn's

Location / extentchoose one

Severitychoose one

Disease phasechoose one

Guides the dietary lens

Context

Assessment

IBD

Notes

• Canadian coverage: most advanced therapies are funded via the Exceptional Access Program (documented activity scores + prior-therapy failure) or private/manufacturer programs — separate 'clinically indicated' from 'publicly fundable now'. Ontario mandates biosimilar switching for originator infliximab/adalimumab.

Suggested drug classesLens: Conventional medical — ACG 2025, ECCO 2024, AGA 2025.

Pick a lens above, then enter disease type and severity to begin.

Switch the lens to compare conventional therapy (5-ASA / biologics / small molecules), dietary approaches (EEN, CDED, Mediterranean), naturopathic options, and Indigenous/traditional perspectives — all evidence-graded.

Guidelines

2025ACG — Ulcerative Colitis in Adults (update) / Crohn's Disease in Adults link
2024ECCO — Guidelines on Therapeutics in Crohn's (2024) / UC (2022) link
2025AGA — Living CPG — Moderate-to-Severe UC (2024) / Crohn's (2025) link
2019CAG (Canada) — Toronto UC consensus (2015) / Luminal Crohn's CPG (2019) — Canadian baseline, dated link
2024AGA — Clinical Practice Update: Diet & Nutritional Therapies in IBD link
2020IOIBD — Dietary Guidance from the International Organization for the Study of IBD (Levine) link
2023ESPEN — Guideline on Clinical Nutrition in inflammatory bowel disease link
2024Cochrane / RCTs — Complementary therapies in IBD — evidence graded (curcumin, De Simone probiotic, etc.) link
2024JCAG / cultural safety — IBD Among Indigenous Peoples (storytelling) + cultural-safety literature (diverse, not a single protocol) link

References

[1]ACG Clinical Guidelines: Ulcerative Colitis in Adults (update) and Management of Crohn's Disease in Adults, 2025 (supersede 2018/2019). link
[2]ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment (2024); ECCO UC medical treatment (2022). link
[3]CAG Toronto Consensus — Perianal Fistulizing Crohn's Disease (2018); Luminal Crohn's CPG (2019); Toronto UC consensus (2015). link
[4]AGA Living Clinical Practice Guidelines — Moderate-to-Severe Ulcerative Colitis (2024) and Crohn's Disease (2025). link
[5]ECCO-ESPGHAN paediatric Crohn's guidance — exclusive enteral nutrition as first-line induction. link
[6]Hashash JG, et al. AGA Clinical Practice Update on Diet and Nutritional Therapies in IBD, 2024; IOIBD dietary guidance (Levine, 2020); ESPEN nutrition in IBD (2023). link
[7]Lewis JD, et al. DINE-CD: SCD vs Mediterranean diet for Crohn's (comparable; inflammatory-marker response uncommon in both). Gastroenterology 2021. link
[8]Complementary therapies in IBD — evidence-graded (Cochrane + RCTs): curcumin add-on in UC, De Simone probiotic in pouchitis/UC, negative omega-3, cannabis symptom-only, wormwood thujone caution. link
[9]IBD Among Indigenous Peoples (storytelling; miyo-māhcihowin), JCAG 2024; cultural-safety literature; Indigenous knowledge is diverse and self-determined (CIHR guidelines). link